Modality
Multispecific
MOA
PD-1i
Target
AHR
Pathway
STING
PompeThymomaPV
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
~Aug 2020
→ ~Nov 2021
Phase 2
~Feb 2022
→ ~May 2023
Phase 3
~Aug 2023
→ ~Nov 2024
NDA/BLA
Feb 2025
→ Feb 2029
NDA/BLACurrent
NCT03977112
2,606 pts·Pompe
2025-02→2029-02·Active
2,606 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-212.9y awayPh3 Readout· Pompe
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
NDA/BLA
Active
Catalysts
Ph3 Readout
2029-02-21 · 2.9y away
Pompe
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03977112 | NDA/BLA | Pompe | Active | 2606 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| Terazumab | Recursion | Phase 3 | AHR |